Sophie F. Hill

Sophie F. Hill

Auto-generated profile, based on publicly available information

Sophie F. Hill

Division of Neurology, Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
MMMiriam H. Meisler
Miriam H. Meisler
SHSophie F. Hill
Sophie F. Hill
WYWenxi Yu
Wenxi Yu

14 January 2020 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
GLGuy M. Lenk
Guy M. Lenk
PJPaymaan Jafar‐Nejad
Paymaan Jafar‐Nejad
SHSophie F. Hill
Sophie F. Hill
LHLucas D. Huffman
Lucas D. Huffman
CSCorrine E. Smolen
Corrine E. Smolen
MMMiriam H. Meisler
Miriam H. Meisler
Objective: SCN8A encephalopathy is a developmental and epileptic encephalopathy (DEE) caused by de novo gain‐of‐function mutations of sodium channel Nav1.6 that result in neuronal hyperactivity. Affected individuals exhibit early onset drug‐resistant seizures, developmental delay, and cognitive impairment. This study was carried out to determine whether reducing the abundance of the Scn8a transcript with an antisense oligonucleotide (ASO) would delay seizure onset and prolong survival in a mouse model of SCN8A encephalopathy.Methods: ASO treatment was tested in a conditional mouse model with Cre‐dependent expression of the pathogenic patient SCN8A mutation p.Arg1872Trp (R1872W). This model exhibits early onset of seizures, rapid progression, and 100% penetrance. An Scn1a +/− haploinsufficient mouse model of Dravet syndrome was also treated. ASO was administered by intracerebroventricular injection at postnatal day 2, followed in some cases by stereotactic injection at postnatal day 30.Results: We observed a dose‐dependent increase in length of survival from 15 to 65 days in the Scn8a‐R1872W/+ mice treated with ASO. Electroencephalographic recordings were normal prior to seizure onset. Weight gain and activity in an open field were unaffected, but treated mice were less active in a wheel running assay. A single treatment with Scn8a ASO extended survival of Dravet syndrome mice from 3 weeks to >5 months.Interpretation: Reduction of Scn8a transcript by 25 to 50% delayed seizure onset and lethality in mouse models of SCN8A encephalopathy and Dravet syndrome. Reduction of SCN8A transcript is a promising approach to treatment of intractable childhood epilepsies. Ann Neurol 2020;87:339–346

15 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HYHui Yao
Hui Yao
DHDouglas F. Hannum
Douglas F. Hannum
YZYiwen Zhai
Yiwen Zhai
SHSophie F. Hill
Sophie F. Hill
RARicardo D.’oLiveira Albanus
Ricardo D.’oLiveira Albanus
DMDonna Martin
Donna Martin
CHARGE syndrome, a rare multiple congenital anomaly condition, is caused by haploinsufficiency of the chromatin remodeling protein gene CHD7 (Chromodomain helicase DNA binding protein 7). Brain abnormalities and intellectual disability are commonly observed in individuals with CHARGE, and neuronal differentiation is reduced in CHARGE patient-derived iPSCs and conditional knockout mouse brains. However, the mechanisms of CHD7 function in nervous system development are not well understood. In this study, we asked whether CHD7 promotes gene transcription in neural progenitor cells via changes in chromatin accessibility. We used Chd7 null embryonic stem cells (ESCs) derived from Chd7 mutant mouse blastocysts as a tool to investigate roles of CHD7 in neuronal and glial differentiation. Loss of Chd7 significantly reduced neuronal and glial differentiation. Sholl analysis showed that loss of Chd7 impaired neuronal complexity and neurite length in differentiated neurons. Genome-wide studies demonstrated that loss of Chd7 leads to modified chromatin accessibility (ATAC-seq) and differential nascent expression (Bru-Seq) of neural-specific genes. These results suggest that CHD7 acts preferentially to alter chromatin accessibility of key genes during the transition of NPCs to neurons to promote differentiation. Our results form a basis for understanding the cell stage-specific roles for CHD7-mediated chromatin remodeling during cell lineage acquisition.

22 February 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
HYHui Yao
Hui Yao
SHSophie F. Hill
Sophie F. Hill
JSJennifer M. Skidmore
Jennifer M. Skidmore
ESEthan D. Sperry
Ethan D. Sperry
DSDonald L. Swiderski
Donald L. Swiderski
DMDonna Martin
Donna Martin
CHD7, an ATP-dependent chromatin remodeler, is disrupted in CHARGE syndrome, an autosomal dominant disorder characterized by variably penetrant abnormalities in craniofacial, cardiac, and nervous system tissues. The inner ear is uniquely sensitive to CHD7 levels and is the most commonly affected organ in individuals with CHARGE. Interestingly, upregulation or downregulation of retinoic acid (RA) signaling during embryogenesis also leads to developmental defects similar to those in CHARGE syndrome, suggesting that CHD7 and RA may have common target genes or signaling pathways. Here, we tested three separate potential mechanisms for CHD7 and RA interaction: (a) direct binding of CHD7 with RA receptors, (b) regulation of CHD7 levels by RA, and (c) CHD7 binding and regulation of RA-related genes. We show that CHD7 directly regulates expression of Aldh1a3 , the gene encoding the RA synthetic enzyme ALDH1A3 and that loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects. Together, these studies indicate that ALDH1A3 acts with CHD7 in a common genetic pathway to regulate inner ear development, providing insights into how CHD7 and RA regulate gene expression and morphogenesis in the developing embryo.

11 August 2022 in Epilepsia
Verified
Journal Article
Open access
SHSophie F. Hill
Sophie F. Hill
JZJulie M. Ziobro
Julie M. Ziobro
PJPaymaan Jafar‐Nejad
Paymaan Jafar‐Nejad
FRFrank Rigo
Frank Rigo
MMMiriam H. Meisler
Miriam H. Meisler
Voltage‐gated sodium and potassium channels regulate the initiation and termination of neuronal action potentials. Gain‐of‐function mutations of sodium channel Scn8a and loss‐of‐function mutations of potassium channels Kcna1 and Kcnq2 increase neuronal activity and lead to seizure disorders. We tested the hypothesis that reducing the expression of Scn8a would compensate for loss‐of‐function mutations of Kcna1 or Kcnq2. Scn8a expression was reduced by the administration of an antisense oligonucleotide (ASO). This treatment lengthened the survival of the Kcn1a and Kcnq2 mutants, and reduced the seizure frequency in the Kcnq2 mutant mice. These observations suggest that reduction of SCN8A may be therapeutic for genetic epilepsies resulting from mutations in these potassium channel genes.

13 October 2023 in Frontiers in Neuroscience
Verified
Journal Article
Open access
SHSophie F. Hill
Sophie F. Hill
PJPaymaan Jafar-Nejad
Paymaan Jafar-Nejad
FRFrank Rigo
Frank Rigo
MMMiriam H. Meisler
Miriam H. Meisler
Developmental and epileptic encephalopathies (DEEs) are severe seizure disorders with inadequate treatment options. Gain- or loss-of-function mutations of neuronal ion channel genes, including potassium channels and voltage-gated sodium channels, are common causes of DEE. We previously demonstrated that reduced expression of the sodium channel gene Scn8a is therapeutic in mouse models of sodium and potassium channel mutations. In the current study, we tested whether reducing expression of the potassium channel gene Kcnt1 would be therapeutic in mice with mutation of the sodium channel genes Scn1a or Scn8a. A Kcnt1 antisense oligonucleotide (ASO) prolonged survival of both Scn1a and Scn8a mutant mice, suggesting a modulatory effect for KCNT1 on the balance between excitation and inhibition. The cation channel blocker quinidine was not effective in prolonging survival of the Scn8a mutant. Our results implicate KCNT1 as a therapeutic target for treatment of SCN1A and SCN8A epilepsy.